← All stocks

Avalo Therapeutics, Inc.

AVTX Mostly scheduled
CIK 0001534120 #2500 in the set updated 17 Sep 2026
Bought (12 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$8.30M
$565.64K on a plan · $7.68M straight out of an exercise
Sold at will
$52.01K
1 of 42 sales
Net
−$8.30M
−$52.01K against sales at will

By person

11 insiders · 42 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Sullivan Christopher Ryan
Chief Financial Officer
$3.52M (16) scheduled
−$3.52M
39,900
$703.03K
+3,322%
Doyle Mittie
Chief Medical Officer
$2.98M (17) scheduled
−$2.98M
51,776
$912.28K
+399.1%
VARKI PAUL
Chief Legal Officer
$1.51M (5) scheduled
−$1.51M
32,576
$573.98K
+214.0%
Goldman Jonathan
Director
$162.94K (2) scheduled
−$162.94K
3,166
$55.78K
Chan Mitchell
Director
$72.46K (1) scheduled
−$72.46K
3,166
$55.78K
Riley Jennifer
Chief Strategy Officer
$52.01K (1)
−$52.01K
37,041
$652.65K
+451.1%
NEIL GARRY ARTHUR
Chief Executive Officer
190,314
$3.35M
+317,090%
KAPLAN GILLA
Director
6,333
$111.59K
Truex Samantha
Director
6,333
$111.59K
KANTOFF AARON
Director
6,333
$111.59K
Almenoff June Sherie
Director
4,167
$73.42K

No percentages here. This company's share count has moved by a factor of 5.2 over the window, from 10,393,954 to 53,629,989 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Insider
Date
Role
Action
Shares
Price
Amount
Sullivan Christopher Ryan
10 Sep 2026
Chief Financial Officer
Sold after exercise
10,185
$17.62
$179.46K
Doyle Mittie
28 Aug 2026
Chief Medical Officer
Sold after exercise
679
$20.00
$13.58K
Sullivan Christopher Ryan
18 Aug 2026
Chief Financial Officer
Sold after exercise
31,031
$20.05
$622.32K
Doyle Mittie
17 Aug 2026
Chief Medical Officer
Sold after exercise
1,000
$20.00
$20.00K
Sullivan Christopher Ryan
17 Aug 2026
Chief Financial Officer
Sold after exercise
3,749
$19.94
$74.76K
Sullivan Christopher Ryan
17 Aug 2026
Chief Financial Officer
Sold after exercise
37,945
$19.85
$753.33K
Riley Jennifer
11 Aug 2026
Chief Strategy Officer
Sell
2,655
$19.59
$52.01K
Doyle Mittie
10 Aug 2026
Chief Medical Officer
Sold after exercise
679
$20.00
$13.58K
Doyle Mittie
27 Jul 2026
Chief Medical Officer
Sold after exercise
1,000
$20.00
$20.00K
Doyle Mittie
30 Jun 2026
Chief Medical Officer
Sold after exercise
4,654
$20.00
$93.08K
Doyle Mittie
23 Jun 2026
Chief Medical Officer
Sold after exercise
1,450
$18.00
$26.10K
Doyle Mittie
28 May 2026
Chief Medical Officer
Sold after exercise
679
$16.00
$10.86K
Doyle Mittie
15 May 2026
Chief Medical Officer
Sold after exercise
3,000
$18.76
$56.28K
Sullivan Christopher Ryan
7 May 2026
Chief Financial Officer
Sold after exercise
18,606
$24.12
$448.82K
Chan Mitchell
6 May 2026
Director
Sold on a plan
3,167
$22.88
$72.46K
Doyle Mittie
6 May 2026
Chief Medical Officer
Sold after exercise
10,058
$22.88
$230.13K
Doyle Mittie
6 May 2026
Chief Medical Officer
Sold after exercise
19,015
$22.41
$426.05K
Doyle Mittie
6 May 2026
Chief Medical Officer
Sold after exercise
44,944
$21.20
$952.67K
Doyle Mittie
6 May 2026
Chief Medical Officer
Sold after exercise
5,000
$19.65
$98.25K
Doyle Mittie
6 May 2026
Chief Medical Officer
Sold after exercise
27,538
$18.03
$496.41K
Sullivan Christopher Ryan
6 May 2026
Chief Financial Officer
Sold after exercise
8,900
$22.57
$200.91K
Sullivan Christopher Ryan
6 May 2026
Chief Financial Officer
Sold after exercise
9,219
$21.37
$197.01K
Sullivan Christopher Ryan
6 May 2026
Chief Financial Officer
Sold after exercise
2,700
$20.76
$56.05K
Sullivan Christopher Ryan
6 May 2026
Chief Financial Officer
Sold after exercise
12,347
$19.28
$238.09K
Sullivan Christopher Ryan
6 May 2026
Chief Financial Officer
Sold after exercise
13,834
$18.55
$256.66K
VARKI PAUL
6 May 2026
Chief Legal Officer
Sold after exercise
400
$23.71
$9.48K
VARKI PAUL
6 May 2026
Chief Legal Officer
Sold after exercise
9,253
$22.70
$210.03K
VARKI PAUL
6 May 2026
Chief Legal Officer
Sold after exercise
22,839
$21.22
$484.54K
VARKI PAUL
6 May 2026
Chief Legal Officer
Sold after exercise
5,196
$19.78
$102.78K
VARKI PAUL
6 May 2026
Chief Legal Officer
Sold after exercise
37,375
$18.91
$706.84K
Doyle Mittie
5 May 2026
Chief Medical Officer
Sold after exercise
1,679
$16.00
$26.86K
Sullivan Christopher Ryan
30 Apr 2026
Chief Financial Officer
Sold on a plan
8,457
$13.23
$111.85K
Sullivan Christopher Ryan
29 Apr 2026
Chief Financial Officer
Sold on a plan
8,458
$13.09
$110.74K
Doyle Mittie
6 Apr 2026
Chief Medical Officer
Sold after exercise
3,970
$18.01
$71.51K
Sullivan Christopher Ryan
2 Apr 2026
Chief Financial Officer
Sold on a plan
1,780
$17.57
$31.27K
Sullivan Christopher Ryan
2 Apr 2026
Chief Financial Officer
Sold on a plan
6,200
$17.02
$105.55K
Doyle Mittie
1 Apr 2026
Chief Medical Officer
Sold after exercise
679
$16.00
$10.86K
Sullivan Christopher Ryan
1 Apr 2026
Chief Financial Officer
Sold on a plan
7,479
$16.83
$125.84K
Sullivan Christopher Ryan
1 Apr 2026
Chief Financial Officer
Sold on a plan
500
$15.86
$7.93K
Doyle Mittie
16 Mar 2026
Chief Medical Officer
Sold after exercise
25,492
$16.15
$411.61K
Goldman Jonathan
14 Nov 2025
Director
Sold after exercise
8,200
$14.35
$117.65K
Goldman Jonathan
14 Nov 2025
Director
Sold after exercise
3,167
$14.30
$45.29K

What was left out

Form 4 filings counted 65
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 7
Sales straight out of an exercise 34
Sales at will 1
Transactions with no price 0
Shares from compensation/vesting 765,263
History held since 3 Oct 2016